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Abstract: Capillary leak syndrome (CLS) is a rare disease with profound vascular leakage, which can
be associated with a high mortality. There have been several reports on CLS as an adverse effect of
anti-cancer agents and therapy, but the incidence of CLS according to the kinds of anti-cancer drugs
has not been systemically evaluated. Thus, the aim of our study was to comprehensively meta-analyze
the incidence of CLS by different types of cancer treatment or after bone marrow transplantation
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(BMT). We searched the literatures (inception to July 2018) and among 4612 articles, 62 clinical
trials (studies) were eligible. We extracted the number of patients with CLS, total cancer patients,
name of therapeutic agent and dose, and type of cancer. We performed a meta-analysis to estimate
the summary effects with 95% confidence interval and between-study heterogeneity. The reported
incidence of CLS was categorized by causative drugs and BMT. The largest number of studies reported
on CLS incidence during interleukin-2 (IL-2) treatment (n = 18), which yielded a pooled incidence
of 34.7% by overall estimation and 43.9% by meta-analysis. The second largest number of studies
reported on anti-cluster of differentiation (anti-CD) agents (n = 13) (incidence of 33.9% by overall
estimation and 35.6% by meta-analysis) or undergoing BMT (n = 7 (21.1% by overall estimation and
21.7% by meta-analysis). Also, anti-cancer agents, including IL-2 + imatinib mesylate (three studies)
and anti-CD22 monoclinal antibodies (mAb) (four studies), showed a dose-dependent increase in the
incidence of CLS. Our study is the first to provide an informative overview on the incidence rate of
reported CLS patients as an adverse event of anti-cancer treatment. This meta-analysis can lead to
a better understanding of CLS and assist physicians in identifying the presence of CLS early in the
disease course to improve the outcome and optimize management.
Keywords: capillary leak syndrome; cancer; interleukin-2; anti-CD agents; bone marrow
transplantation
1. Introduction
Capillary leak syndrome (CLS), also known as vascular leak syndrome (VLS), is a rare but fatal
disease, and an idiopathic form of CLS was first reported by Clarkson in 1960 [1]. Patients with CLS show
a profound increase of capillary permeability, which can result in the leakage of plasma with proteins
out from capillaries, resulting in clinical features such as edema, hypotension, hypoalbuminemia, or
hemoconcentration [2–4]. Most cases of CLS are classified as idiopathic forms, and its pathogenesis has
not been elucidated yet. It may also develop as a secondary form, preceded by autoimmune diseases,
infections, snakebites, and drugs [5]. Cancer and chemotherapy are also considered to be important
causes of secondary CLS, but the underlying mechanisms remain mostly elusive [4,6]. CLS shows
a high mortality rate, with one-year and five-year survival rates being 89% and 73%, respectively,
in idiopathic forms [7]. If prophylactic treatment including intravenous immunoglobulin (IVIG) is
provided, disease-specific mortality seems to decrease in idiopathic CLS [3,7,8]. However, there is no
established treatment for secondary CLS, and supportive therapy with fluid management may be the
most important element [5]. Currently, exact treatment guidelines for CLS do not exist [8–11]. Moreover,
the capillary leak phenomenon can be similar between idiopathic CLS and secondary forms of CLS due
to drugs, but the pathophysiology of them may be somewhat different.
CLS has also been reported as an adverse event in cancer patients receiving different types of
anti-cancer treatments [3]. However, there has been a lack of awareness of CLS by oncologists due to
the non-specific symptoms of this disease [3], and the incidence of CLS according to the different types
of anti-cancer agents or therapy has not been systematically investigated.
Thus, in this study, we conducted a systematic review and meta-analysis to estimate the incidence
proportion of CLS in cancer patients who received specific anti-cancer treatment or therapy, including
bone marrow transplantation (BMT).
2. Methods
2.1. Literature Search Strategy and Study Selection
We followed the guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) checklist for this systematic review (Supplementary Table S1). Two investigators (K.H.L. and
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I.R.L.) manually searched the literature (PubMed and EMBASE) to find original studies that reported
cases of CLS as an adverse event in cancer patients who received specific cancer treatment or BMT.
The search terms were: “(Capillary leak OR Vascular leak) AND (cancer OR carcinoma OR neoplasm
OR tumor)”, and the date of the last search was 15 July 2018. If there was a discrepancy for the
inclusion/exclusion of the respective article, it was discussed and resolved by consensus among three
investigators (J.I.S., K.H.L., and I.R.L.). The full literature search strategy is presented in Figure 1.
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The eligibility criteria for inclusion were: studies on (1) CLS that was an adverse event of cancer
treatment-related drugs; and (2) CLS that developed after BMT; and the exclusion criteria were: studies
on (1) CLS that were caused by idiopathic forms, infection, or surgery; and (2) CLS attributed to cancer
itself, or (3) missing raw data from the original study reporting on CLS as an adverse event of cancer
treatment. Our initial search yielded 4612 articles, but we finally included 62 clinical trials (or studies)
that met the inclusion criteria for this systematic review.
2.2. Data Extraction
For each eligible clinical trial (or study), we recorded the first author, publication year, journal
name, period of study, country, total number of patients, number of patients who developed CLS,
diagnosed cancer type, causative drugs, and the dose of drugs.
2.3. Analyses of Clinical Trials (or Studies)
The incidence of CLS for each study was estimated by calculating the ratio between the number
of CLS patients and the total number of cancer patients who received the causative drug or BMT. The
data for each study are presented in Table 1 [12–73]. To estimate the incidence of CLS for the relevant
groups, we presented the data with median (ranges) and also performed a meta-analysis to estimate
the summary effects with proportion of CLS and 95% confidence interval (CI) using random-effect
models [74,75]. Random effects meta-analysis provides the weighted average of the effect sizes of a
group of studies with the assumption that individual studies are estimating different effects [76]. We
evaluated the between-study heterogeneity using the I2 metric of inconsistency and P value of the
χ2-based Cochran Q test. I2 is the ratio of the between-study variance over the sum of the within-study
and between-study variances, and it ranges between 0–100%. I2 values of <25%, 25–50%, and >75% are
usually judged to represent low, moderate (large), and high (very large) heterogeneity, respectively [77].
Since statistical tests for heterogeneity are not very powerful, a higher p value than usual (p < 0.10:
significant heterogeneity) is used as the cut-off for clinical heterogeneity [78].
2.4. Statistical Analysis
To meta-analyze the incidence of CLS according to the causative anti-cancer drugs or after BMT,
the summary effects with 95% CI and the between-study heterogeneity were analyzed by using
MedCalc version 15.8 software (MedCalc Software, Ostend, Belgium).
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Table 1. Summary profiles of clinical trials that reported capillary leak syndrome as an adverse event of anti-cancer drugs.
Ref. No. Author, Year ofPublication
Period of
Study Country Total Number CLS Incidence (%) Diagnosis Drug Treatment Dose
IL-2
[12] Atkins et al., 1999 1985–1993 USA 270 92 34.1 Melanoma IL-2 720,000 IU/kg every 8 h
[13] Sparano et al., 1993 1988–1992 USA 44 40 90.9 Melanoma IL-2 6 × 106 IU/m2 every 8 h
[14] Tarhini et al., 2007 2000–2003 USA 26 7 26.9 Melanoma IL-2 600,000 IU/kg every 8 h for up to14 doses for 2 cycles
[15] Talpur et al., 2012 2003–2008 USA 8 6 75.0 Cutaneous peripheral T-cell lymphoma IL-2 Dose level 18 µg/kg
[16] Gallagher et al, 2007 2006 Israel 14 14* 100.0 Melanoma, renal cell carcinoma IL-2 Dose level 8–14 µg/kg
[17] Shusterman et al., 2010 NA USA 39 12 30.8 Neuroblastoma IL-2 Dose level 12 mg/m2
[18] Shaughnessy et al., 2005 NA USA 2 1 50.0
Non-Hodgkin lymphoma, Hodgkin disease,
acute leukemia, myelodysplastic syndrome,
chronic myelogenous leukemia, multiple
myeloma, aplastic anemia
IL-2 Dose level 9.0 µg/kg
[18] Shaughnessy et al., 2005 NA USA 20 2 10.0
Non-Hodgkin lymphoma, Hodgkin disease,
acute leukemia, myelodysplastic syndrome,
chronic myelogenous leukemia, multiple
myeloma, aplastic anemia
IL-2 Dose level 4.5 µg/kg
[19] Frankel et al., 2003 NA USA 18 2 11.1 Chronic lymphocytic leukemia IL-2 Dose level 9 or 18 µg/kg
[20] Duvic et al., 2002 NA USA 71 18 25.4 Cutaneous T-cell lymphoma IL-2 Dose level 9 or 18 µg/kg
[21] Foss et al., 2001 NA USA 15 2 13.3 Cutaneous T-cell lymphoma IL-2 Dose level 9 or 18 µg/kg
[22] Sievers et al., 2000 NA USA 60 7 11.7 Acute myelogenous leukemia IL-2 9,000,000 IU/m
2 for 4 days and
16,000,000 IU/m2 for 10 days
[23] Duvic et al., 1998 NA USA 4 1 25.0 Cutaneous T cell lymphoma IL-2 Dose level 9 or 18 µg/kg
[24] Meehan et al., 1997 1993–1995 USA 57 3 5.3 Breast cancer IL-2 MTD 6 × 106 IU/m2/day
[25] Chang et al., 1993 NA Japan 20 15 75.0 Melanoma, renal cell cancer IL-2
Using vaccine-primed lymph
node cell with IL-2
(180,000 IU/kg)
[26] van Haelst Pisani Cet al., 1991 NA France 5 4 80.0 Melanoma, renal cell cancer IL-2
Human recombinant IL-2
3 × 106 IU/m2/24 h for
4 or 5 days
[27] Philip et al., 1989 1987–1988 France 20 8 40.0 Renal cell cancer IL-2
IL-2 3 × 106 IU/m2 with
lymphapheresis(17), IL-2 3 × 106
IU/m2(3)
[28] Carey et al., 1997 NA UK 10 10* 100.0 Malignant melanoma, renal cell cancer IL-2 Using 3 × 10
6 IU/m2/day for
5 days
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Table 1. Cont.
Ref. No. Author, Year ofPublication
Period of
Study Country Total Number CLS Incidence (%) Diagnosis Drug Treatment Dose
IL-2 with other agents
[16] Gallagher et al., 2007 2006 Israel 4 4 100.0 Renal cell carcinoma
IL-2
+
bevacizumab
IL-2 dose level 9–14 µg/kg
[29] Pautier et al., 2013 NA France 3 0 0.0
Melanoma, ovarian adenocarcinoma,
Merkel-cell carcinoma, gastrointestinal
stromal tumor, rectal adenocarcinoma,
cervical adenocarcinoma
IL-2
+ imatinib
mesylate
IL-2: 3,000,000 IU/day, imatinib
mesylate 400 mg/day
[29] Pautier et al., 2013 NA France 11 1 9.0
Melanoma, ovarian adenocarcinoma,
Merkel-cell carcinoma, gastrointestinal
stromal tumor, rectal adenocarcinoma,
cervical adenocarcinoma
IL-2
+ imatinib
mesylate
IL-2: 6,000,000 IU/day, imatinib
mesylate 400 mg/day
[29] Pautier et al., 2013 NA France 3 1 33.3
Melanoma, ovarian adenocarcinoma,
Merkel-cell carcinoma, gastrointestinal
stromal tumor, rectal adenocarcinoma,
cervical adenocarcinoma
IL-2
+ imatinib
mesylate
IL-2: 9,000,000 IU/day, imatinib
mesylate 400 mg/day
[30] O’Brien et al., 2006 NA Ireland 10 0 0.0 Melanoma IL-2+ taurolidine
IL-2 72 MIU/m2 for 120 h
Taurolidine 2% w/v via
continuous infusion
[31] Pichert et al., 1991 1988–1989 Switzerland 14 14* 100.0 Renal cell carcinoma, melanoma IL-2+ IFN-alfa 2a
IL-2 3 MIU/m2 for 4 days
IFN-alpha 6 MIU/m2 for 2 days
(1, 4 day)
[13] Sparano et al., 1993 1988–1992 USA 41 33 80.5 Melanoma IL-2+ IFN-alfa
IL-2 4.5 × 106 IU/m2 per dose
IFN-alpha 2 4.5 × 106 IU/m2
[32] Gilman et al., 2009 1997–2002 USA 19 3 15.8 Neuroblastoma IL-2 + ch14.18 Ch14.18 20 and 40 mg/m
2/day
IL-2 4.5 × 106 IU/m2/day
[33] Meehan et al., 2010 NA USA 12 2 16.7 Multiple myeloma, non-Hodgkinlymphoma
IL-2 +
GM-CSF +
G-CSF
IL-2 6 × 105–1.5 × 106 IU/m2
G-CSF 5 µg/kg
GM-CSF 7.5 µg/kg
[34] Yu et al., 2010 2001–2009 USA 226 51 22.6 Neuroblastoma
IL-2
+ GM-CSF
+ anti-GD2
+
isotretionoin
IL-2 3.0 × 106 IU/m2 (week 1),
4.5 × 106 IU/m2 (week 2)
GM-CSF 250 µg/m2
isotretionoin 160mg/m2
[35] Hamblin et al., 1993 1988–1989 UK 16 1 6.3 Metastatic colorectal cancer IL-2 + 5-FU
IL-2 18 × 10 IU/m2/day over
120 h
5FU 600 mg/m2
[36] Savage et al., 1997 NA UK 24 6 25.0 Metastatic renal cancer IL-2 + 5-FU IL-2 9 × 10
6 IU
5-FU 200 mg/m2
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Table 1. Cont.
Ref. No. Author, Year ofPublication
Period of
Study Country Total Number CLS Incidence (%) Diagnosis Drug Treatment Dose
IL-1 with other agents
[37] Smith et al., 1993 1990–1992 USA 15 6 40.0
Colon cancer, melanoma, renal cell cancer,
lung cancer, pancreatic cancer, liposarcoma,
adenocarcinoma with unknown primary site
IL-1 alpha +
carboplatin
IL-1 alpha 0.03, 0.1, 0.3 µg/kg
carboplatin 800 mg/m2
[38] Worth et al., 1997 1994 USA 9 4 44.4 Osteosarcoma IL-1 alpha +etoposide
IL-1 alpha 0.1 µg/kg
etoposide 100 mg/m2
IL-4
[39] Sosman et al., 1994 NA USA 17 2 11.8 Renal cell carcinoma, melanoma, coloncarcinoma, cholangiocarcinoma IL-4+IL-2
IL-4 40–600 µg /m2/day
IL-2 11.2 MIU/m2/day
GM-CSF
[40] Gorin et al., 1992 1988–1990 France 44 3 6.8 Non-Hodgkin lymphoma GM-CSF Dose level 250 µg/m2
[41] Liberati et al., 1991 NA Italy 14 1 7.1 Non-Hodgkin lymphoma GM-CSF Dose level 5 µg/kg
[42] Steward et al., 1989 NA USA&UK 20 3 15.0 Metastatic solid tumors GM-CSF
Using dose 0.3, 1.0, 3.0, 10, 30,
and 60 µg/kg/day
Dose level 32 µg /kg
Gemcitabine
[43] Jidar et al., 2009 NA France 23 1 4.3 Cutaneous T-cell lymphoma Gemcitabine Using dose 700–1000 mg/m2
[44] Kurosaki et al., 2009 2003–2006 Japan 27 1 3.7 Pancreatic cancer Gemcitabine Dose level 1000 mg/m2 biweekly
[45] Dumontet et al., 2001 1988–2000 France 36 1 2.8 Non-Hodgkin lymphoma Gemcitabine Dose level 1 g/m2
SS1P
[46] Kreitman et al., 2009 NA USA 24 13 54.2
Peritoneal mesothelioma, pleural
mesothelioma, pleural–peritoneal
mesothelioma, ovarian carcinoma,
pancreatic carcinoma
SS1P Dose level 4–25 µg/kg
[47] Hassan et al., 2007 2000–2006 USA 34 2 5.9
Peritoneal mesothelioma, pleural
mesothelioma, pleural–peritoneal
mesothelioma, ovarian carcinoma,
pancreatic carcinoma
SS1P Dose level 18 or 25 µg/kg
Anti-CD agents
[48] Sausville et al., 1995 NA USA 11 4 36.4 B-cell lymphoma Anti-CD22 Dose level 28.8 mg/m
2
MTD 19.2 mg/m2
[49] Vitetta et al., 1991 NA USA 15 15* 100.0 B-cell lymphoma Anti-CD22 Using dose 12.5, 25, 50, 75,100 mg/m2
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Table 1. Cont.
Ref. No. Author, Year ofPublication
Period of
Study Country Total Number CLS Incidence (%) Diagnosis Drug Treatment Dose
[50] Wayne et al., 2014 NA USA 7 2 28.6 Acute lymphoblastic leukemia Anti-CD22 Dose level 30 µg/kg
[51] Amlot et al., 1993 NA USA 26 3 11.5 B-cell lymphoma Anti-CD22 Using Maximal single dose2.5–13.9 mg/m2
[52] Stathis et al., 2014 NA Switzerland 5 1 20.0 Non-Hodgkin lymphoma Anti-CD22 +temsirolimus
Using dose Anti-CD22
0.8 mg/m2 + temsirolimus
15 mg/day,
Anti-CD22 0.8 mg/m2 +
temsirolimus 10 mg/day
[53] Schindler et al., 2011 NA USA 17 1 5.9 B-cell acute lymphoblastic leukemia Anti-CD19 +anti-CD22 Dose level 8 mg/m
2
[54] Bachanova et al., 2015 NA USA 25 7 28.0
Pre-B acute lymphoblastic leukemia, chronic
lymphocytic leukemia, Non-Hodgkin
lymphoma
Anti-CD19 +
anti-CD22 Dose level 40–60 µg/kg
[55] Schnell et al., 2003 NA Germany 27 3 11.1 Hodgkin lymphoma Anti-CD25 Dose level 15–20 mg/m2
[56] Schnell et al., 2000 NA Germany 18 18* 100.0 Hodgkin lymphoma Anti-CD25 Dose level 15 mg/m2/cycle
[57] Engert et al., 1997 NA Germany 15 1 6.7 Hodgkin lymphoma Anti-CD25
Dose level 5 mg/m2(3),
10 mg/m2(3), 15 mg/m2(6),
20 mg/m2(3)
[58] Schnell et al., 2002 NA Germany 17 3 17.6 Hodgkin lymphoma, Non-Hodgkinlymphoma Anti-CD30
Dose level 7.5 mg/m2(1),
10 mg/m2(2)
MTD 5 mg/m2
[59] Stone et al., 1996 NA USA 23 16 69.6 Non-Hodgkin lymphoma
Anti-CD19
+
IgG-HD37-dgA
MTD 19.2 mg/m2
[60] Uckun et al., 1999 1996–1998 USA 15 1 6.7 Acute lymphoblastic leukemia, chroniclymphocytic leukemia
CD19
receptor
directed
tyrosine
kinase
inhibitor
B43-Genistein
Dose level 0.1 mg/kg
Other agents
[61] Baluna et al., 1996 NA USA 56 12 21.4 Non-Hodgkin lymphoma
Ricin A
chain-containing
immunotoxin
Using IgG-HD37-RTA continuous
infusion 9.6–19.2 mg/m2(2), bolus
infusion range 2–24 mg/m2(2)
IgG-RFB4-RTA continuous
infusion 9.6–28.8 mg/m2(4),
bolus infusion 23–48 mg/m2(2)
Fab’-RFB4-RTA bolus infusion
25–100 mg/m2(2)
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Table 1. Cont.
Ref. No. Author, Year ofPublication
Period of
Study Country Total Number CLS Incidence (%) Diagnosis Drug Treatment Dose
[62] Borghaei et al., 2009 NA USA 39 6 15.4 NSCLC, pancreatic cancer ABR-217620 Dose level 20 µg/kg
[63] Hochhauser et al., 2009 2004–2006 UK 16 10 62.5
Ampulla of vater cancer,
cholangiocarcinoma, colorectal cancer, lung
cancer, esophagus cancer, pancreatic cancer,
sarcoma, malignant melanoma, stomach
cancer
Pyrrolobenzod-
iazepine Using dose 15–240 µg/m
2
[64] Posey et al., 2002 NA USA 46 1 2.2
Colorectal cancer, pancreatic cancer, ovarian
cancer, breast cancer, lung cancer, prostate
cancer, head and neck cancer, stomach
cancer, endometrial cancer, thyroid cancer,
unknown primary lesion
SGN-10
(or BR96
sFv-PE40)
Dose level > or = 0.384 mg/m2
[65] Elias et al., 2001 NA USA 5 4 80.0 Breast cancer Paclitaxel Dose level 150 mg/m2
[66] Grossbard et al., 1993 1990–1991 USA 12 5 41.7 Non-Hodgkin lymphoma Anti-B4-bR
Using dose 20, 40, 50 µg/kg/day
for 7 days
MTD 40 µg/kg
[67] Pazdur et al., 1991 NA USA 17 6 35.3 Metastatic cancer FK973 Using dose 30 mg/m
2(2),
45 mg/m2(4)
[68] Barrett et al., 1982 1980–1981 UK 36 4 11.1
Acute myeloid leukemia, acute
lymphoblastic leukemia, aplastic anemia,
mucopolysaccharidosis, metachromic
leukodystrophy
Dihydro
benzoxazine
Using dose 12.5 mg/kg(10),
500 g/m2(26)
[69] Zwaan et al., 2014 NA
Multicenter
in
Europe†
36 3 8.3 Acute myeloid leukemia Cyclosporine Using dose plasma concentration<100 µg/L
[69] Zwaan et al., 2014 NA
Multicenter
in
Europe†
29 1 3.4 Acute myeloid leukemia
Clofarabine
+ cytarabine
+ liposomal
daunorubicin
Clofarabine 20, 30, 40 mg/m2
Ara-C 2 g/m2/day
dauorubicin 40–60 mg/m2
NA: not available (information was not included in the case series article), CLS: capillary leak syndrome, Using dose: drug dose that was administered to patients, Dose level: serum drug
level when the patients show toxicity, DLT: dose limited toxicity, IL: Interleukin, w/v: weight/volume percentage, ch14.18: a chimeric human/murine anti-GD2 antibody, MIU: million
international units, GVHD: graft-versus-host disease, INF: interferon, GM-CSF: granulocyte-macrophage colony-stimulating factor, G-CSF: granulocyte-colony stimulating factor, 5-FU:
5-fluorouracil, SS1P: recombinant anti-mesothelin immunotoxin, CD: cluster of differentiation, MTD: maximum tolerated dose, NSCLC: Non small cell lung cancer, ABR-217620:
naptumomab estafenatox, SGN-10: a single-chain immunotoxin, Anti-B4-bR: B-cell restricted immunotoxin anti-B4-blocked ricin, FK973: novel, substituted dihydro benzoxazine
structurally similar to mitomycin, USA: United States of America, UK: United Kindom; *All study patients developed capillary leak syndrome after receiving anti-cancer agents. There
were no capillary leak syndrome features before treatment. † Study population was collected from multiple centers in Europe: Netherlands, Austria, Germany, France, the Czech Republic,
and the United Kingdom.
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3. Results
There were 62 clinical trials (or studies) that reported on the incidence of CLS in patients receiving
anti-cancer treatments or after BMT. Most of these studies were clinical trials in which the incidence
of CLS was reported as an adverse event of anti-cancer treatment (Table 1) [12–73]. Among these, six
studies reported on CLS associated with BMT with or without other agents (Table 2) [40,42,70–73].
The results of meta-analyses on the incidence of CLS induced by various drugs in cancer patients are
summarized in Table 3 and Supplementary Figure S1a–n.
There were 18 studies that reported on the incidence of CLS associated with the use of interleukin-2
(IL-2), which ranged from 5.3% to 100%. The incidence of CLS by IL-2 was 34.7% by overall estimation
and 43.9% by meta-analysis. Although varying treatment doses were used, no correlations were
found between the dose of IL-2 and the overall incidence of CLS. IL-2 was used in combination
with other agents in several studies. These included combinations with bevacizumab (one study),
imatinib mesylate (one study, three dose-related results), taurolidine (one study), interferon (IFN)-alpha
(two studies), chimeric human/murine anti-GD2 ch14.18 monoclonal antibody (mAb) (one study),
granulocyte-macrophage colony-stimulating factor (GM-CSF) + granulocyte colony-stimulating factor
(G-CSF) (one study), GM-CSF + anti-GD2 mAb + isotretinoin (one study) and 5-fluorouracil (5-FU)
(two studies). The incidence of CLS in patients treated with IL-2 with other agents was 29.1% by
overall estimation and 32.0% by meta-analysis. We found that the highest incidence of CLS (80.5% and
100%) was observed when IL-2 was combined with IFN-alpha. In the IL-2 + imatinib mesylate group,
there was a dose-related increase in the incidence of CLS (0%→ 9%→ 33.3%). The incidence of CLS in
patients who received IL-2 + bevacizumab (IL-2 dose: 9 µg/kg) was 100%. In cases with concomitant
IL-2 + 5-FU treatment, the incidence of CLS varied from 6.3% to 25.0%, resulting in 17.5% by overall
estimation and 17.1% by meta-analysis.
Two studies reported on the incidence of CLS associated with the use of IL-1 in combination
with carboplatin (one study, 40% CLS incidence) or etoposide (one study, 44.4%). Three studies
reported on the incidence of CLS associated with the use of GM-CSF, which ranged from 6.8% to
15.0%. The incidence of CLS in patients treated with GM-CSF was low (9.0%) by overall estimation
and 10.1% by meta-analysis. The incidence of CLS by GM-CSF was 9.0% by overall estimation and
10.1% by meta-analysis.
Three studies reported on the incidence of CLS associated with the use of gemcitabine, which was
very low (2.8–4.3%). The incidence of CLS caused by gemcitabine was 3.5% by overall estimation and
4.9% by meta-analysis. There were two studies that reported on the incidence of CLS associated with
the use of SS1P (recombinant anti-mesothelin immunotoxin), which was 5.9% and 54.2%, and showed
no dose-response.
Thirteen studies reported on the incidence of CLS associated with the use of various kinds of
anti-cluster of differentiation (CD) agents, which ranged from 5.9% to 100%. The incidence of CLS by
various kinds of anti-CD agents was 33.9% by overall estimation and 35.6% by meta-analysis. There
were four studies that reported on the incidence of CLS associated with the use of anti-CD22 mAb,
which ranged from 11.5% to 100%. The incidence of CLS by various kinds of anti-CD22 mAb was
40.7% by overall estimation and 48.1% by meta-analysis. It appeared that there was an increasing
incidence of CLS with an increasing treatment dose of anti-CD22 mAb. The addition of anti-CD19
mAb to anti-CD22 mAb treatment did not result in a further increase in the incidence of CLS. Three
studies reported on the incidence of CLS associated with the use of anti-CD25, which ranged from
6.7% to 100%. The incidence of CLS by various kinds of anti-CD25 was 36.7% by overall estimation
and 42.2% by meta-analysis.
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Table 2. Summary profiles of clinical studies that reported capillary leak syndrome related to bone marrow transplantation.
Ref. No. Author, Year TotalNumber CLS
Incidence
(%) Diagnosis Hypothesis or Risk Factors
Only BMT related
[70] Cahill, et al., 1996 55 29 52.7 Both allogeneic and autologous transplantrecipients Pivotal contribution by circulating leukocytes
[71] Nurnberger, et al., 1993 12 4 33.3
Acute lymphoblastic leukemia
Aplastic anemia
Fanconi’s anemia
Neuroblastoma
Ewing’s sarcoma
Lymphoepithelial carcinoma
C1 Inhibitor activity decreased to 0.60-fold to 0.80-fold
Elevated C4d concentrations (up to 2.4 mg/dL, upper
normal threshold value: 0.9)
[72] Nurnberger, et al., 1997 96 20 20.8
Acute lymphoblastic leukemia
Acute myeloblastic leukemia
Chronic myeloblastic leukemia
Severe aplastic anemia
Ewing tumors
Rhabdomyosarcoma
Neuroblastoma
Lymphoepithelioma
Receiving G-CSF or GM-CSF*
GVHD prophylaxis : MTX plus cyclosporine A
Allogeneic-related BMT, solid tumor
Unrelated BMT, hematologic disease
Patients with high-risk pretreatment
[40] Gorin et al., 1992 44 3 6.8 Non-Hodgkin’s lymphoma BMT after using GM-CSF* ( Dose level 250 µg/m2)
[42] Steward et al., 1989 20 3 15.0 Metastatic solid tumors BMT after using GM-CSF* (Using dose 0.3, 1.0, 3.0, 10,30, and 60 µg/kg/day, dose level 32 µg/kg)
[72] Nurnberger, et al., 1997 142 22 15.5
Acute lymphoblastic leukemia
Chronic myelomonocytic leukemia
Severe aplastic anemia
Fanconi’s anemia
Non-Hodgkin’s lymphoma,
Ewing tumor
Neuroblastoma
Rhabdomyosarcoma
Wiskott–Aldrich syndrome
BMT after using G-CSF*
Low levels of C1 esterase inhibitor†
[73] Salat et al, 1995 48 7 14.6
Acute lymphoblastic leukemia
Acute myeloblastic leukemia
Chronic myeloblastic leukemia
Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma
Severe aplastic anemia
Multiple myeloma
Elevation of terminal complement complex (TCC) levels
Elevation of functional Cl-esterase inhibitor (CI-INH)
Elevation of Cl-inhibitor antigen (CI-INH antigen)
CLS: capillary leak syndome, GM-CSF: granulocyte-macrophage colony-stimulating factor, G-CSF: granulocyte-colony stimulating factor, GVHD: Graft-versus-host disease,
MTX: methotrexate, BMT: bone marrow transplantation; * These patients initially received bone marrow transplantation, and then received GM-CSF to correct neutropenia; † To correct
this status, 15 severe CLS patients were treated with C1 INH concentrate using a cumulative dose of 180 units/kg in this article.
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Table 3. Meta-analyses on the incidence of capillary leak syndrome induced by various anti-cancer drugs or after BMT in cancer patients.
Causative Drugs NumberofStudies
Total Number of
Patients
Number of
CLS
Incidence of CLS
(Overall)
Incidence of CLS by
Meta-Analysis
(95%CI)
Heterogeneity I2
(p Value)
Incidence of CLS
Median (Ranges)
IL-2 18 703 244 34.7% 43.9% (29.5–58.9) 92.6% (p < 0.0001) 32.4% (5.3–100)
IL-2 with other agents 13 405 118 29.1% 32.0% (15.6–51.1) 91.1% (p < 0.0001) 16.7% (0–100)
IL-2 + IFN-alpha 2a 2 55 47 85.5% 90.4% (64.1–100) 80.0% (p = 0.0255) 90.3% (80.5–100)
IL-2 + imatinib mesylate 3 17 2 11.8% 15.0% (3.1–33.4) 0% (p = 0.4889) 9.0% (0–33.3)
IL-2 + bevacizumab 1 4 4 100.0% - - -
IL-2 + 5-FU 2 40 7 17.5% 17.1% (3.7–37.4) 56.1% (p = 0.1312) 33.3% (6.3–25.0)
IL-1 with other agents 2 24 10 41.7% 42.3% (24.3–61.4) 0% (p = 0.8266) 42.2% (40–44.4)
IL-4 (+IL-2) 1 17 2 11.8% - - -
GM-CSF 3 78 7 9.0% 10.1% (4.6–17.6) 0% (p = 0.5802) 7.1% (6.8–15.0)
Gemcitabine 3 86 3 3.5% 4.9% (1.4–10.3) 0% (p = 0.9273) 3.7% (2.8–4.3)
SS1P 2 58 15 25.9% 26.9 (0.00–78.6) 94.5% (p < 0.0001) 30.1 (5.9–54.2)
Anti-CD agents 13 221 75 33.9% 35.6% (16.1–60.0) 91.8% (p < 0.0001) 20.0% (5.9–100)
Anti-CD22 4 59 24 40.7% 48.1% (6.3–91.7) 93.7 (p < 0.0001) 44.1% (11.5–100)
Anti-CD19 + anti-CD22 2 42 8 19.0% 17.8% (2.7–42.2) 69.6% (p = 0.0699) 17.0% (5.9–28.0)
Anti-CD25 3 60 22 36.7% 42.2% (0.02–98.0) 97.0% (p < 0.0001) 11.1% (6.7–100)
BMT 7 417 88 21.1% 21.7% (12.2–33.1) 83.9% (p < 0.0001) 15.5% (6.8–52.7)
Only BMT-related 3 163 53 32.5% 35.5% (14.7–59.6) 87.5% (p = 0.0003) 33.3% (20.8–52.7)
BMT with other agents 4 254 35 13.8% 14.2% (10.2–18.7) 0% (p = 0.5001) 14.8% (6.8–15.5)
CLS: capillary leak syndome, IL: interleukin, GM-CSF: granulocyte-macrophage colony-stimulating factor, 5-FU: 5-fluorouracil, SS1P: recombinant anti-mesothelin immunotoxin, CD:
cluster of differentiation, BMT: bone marrow transplant.
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There were single studies reporting on other drugs associated with CLS in cancer patients, with
an incidence of CLS ranging from 3.4% to 80%. The incidence of CLS was high with the use of
pyrrolobenzodiazepine (one study, 62.5%), paclitaxel (one study, 80.0%), and moderate with the
use of anti-B4-bR (B-cell restricted immunotoxin anti-B4-blocked ricin) (one study, 41.7%), FK973
(novel, substituted dihydro benzoxazine structurally similar to mitomycin) (one study, 35.3%), and
low with the use of SGN-10 (a single-chain immunotoxin) (one study, 2.2%), clofarabine + cytarabine +
liposomal daunorubicin (one study, 3.4%), cyclosporine (one study, 8.3%), dihydro benzoxazine (one
study, 11.1%), ABR-217620 (naptumomab estafenatox) (one study, 15.4%), and ricin A chain-containing
immunotoxin (one study, 21.4%).
There were seven studies reporting the incidence of CLS associated with BMT with or without
other agents, which ranged from 6.8% to 52.7%. The incidence of CLS associated with BMT was 21.1%
by overall estimation and 21.7% by meta-analysis (Tables 2 and 3, Supplementary Figure S1o).
4. Discussion
CLS is an important medical condition that is characterized by the escape of blood plasma
into the interstitial space, resulting in edema, hypoalbuminemia, hemoconcentration, and low blood
pressure [2]. The pathogenesis of secondary CLS due to anti-cancer treatment is not well-known, but
there are several studies supporting the role of pathogenic molecules of idiopathic CLS including
multiple cytokines, angiopoietin-2, and vascular endothelial growth factor (VEGF) [5,10,79,80],
although the pathophysiology of idiopathic and secondary CLS may be somewhat different, because
CLS by anti-cancer drugs could also develop due to a direct toxicity to the capillary system. These
molecules are mostly related to an increase in the permeability of vascular endothelial cells leading to
vascular leakage. Especially, multiple animal studies suggest that IL-2 causes the acute injury of normal
tissues by enhancing neutrophil adhesion and generating reactive oxygen intermediates, proteases,
and pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF alpha), which can cause a
vascular leakage [81,82]. The proposed pathogenesis of CLS is demonstrated in Figure 2.
Evaluating the incidence of CLS is challenging because the clinical presentations of CLS are
non-specific, and it is expected that cases have been misdiagnosed in the past. Recently, CLS has
been increasingly diagnosed due to increased awareness of the disease [4]. CLS due to anti-cancer
drugs has been sporadically reported in the literature, and it has recently been registered in VigiBase
(http://www.vigiaccess.org/), the World Health Organization global Individual Case Safety Report
(ICSR) database, which contains reports of suspected adverse drug reactions (ADRs) collected by
national drug authorities in more than 130 countries between 1967 and February 2018 [10]. However,
it did not report the incidence rate of CLS for patients treated with anti-cancer drugs, and our study
firstly reported the incidence of CLS according to the drugs or after BMT by meta-analysis.
Due to the lack of an overall understanding of CLS as an adverse effect of anti-cancer treatment,
we carried out a systematic analysis of published clinical trials (or studies) to evaluate the incidence
of anti-cancer treatment-related CLS. Through calculating the number of CLS among total patients
reported in clinical trials (or studies), we were able to estimate the pooled incidence of CLS when
patients were treated with several anti-cancer treatment-related drugs and after BMT. The most studied
drug was IL-2, which was used as a cancer immunotherapy, and the incidence of CLS was 34.7% by
overall estimation, suggesting that it may be a common adverse effect, and that the phenomenon of
CLS has been underestimated in cancer patients in the past. In addition, the incidence of CLS in cancer
patients differed according to the specific drug or drug combinations that were used and ranged from
5.3% to 100.0%. Therefore, our analysis shows important results that oncologists should be aware of.
However, these studies did not report on the treatment strategies or clinical outcome of CLS, because
most studies reported CLS as an adverse event of the drug. The clinical and laboratory data, treatment
modalities, and mortality rate of patients and contributing factors leading to mortality of CLS in cancer
are well analyzed in our recent systematic review of sporadic case reports [4].
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Figure 2. The proposed pathogenesis of capillary leak syndrome (CLS). Some pathogenic molecules in
CLS show increased levels in sera, which triggers endothelial cell damage and plasma leakage from
vessels. This is supposed to eventually result in the classic triad of symptoms (hypoalbuminemia,
hemoconcentration, and hypotension) and normal tissue damages. VEGF: vascular endothelial growth
factor, IL: Interleukin, TNF: Tumor necrosis factor, IFN: Interferon, ET: endothelin, CCL: chemokine
ligand, Ang2: angiopoietin-2.
We also found that BMT may be an important risk factor for CLS in cancer patients. The
incidence of CLS associ ted with BMT with or without other agents ranged from 6.8% to 52.7%.
The pathophysiology of CLS in BMT-related CLS has ot been fully stu ied, but some hypotheses on
the contributing factors have been suggested such as pivotal contribution by circulating leukocytes,
decreased C1 esterase inhibitor activity, elevated C4d concentrations, the use of G-CSF or GM-CSF,
and elevation of terminal complement complex (TCC) levels [70–73]. Future studies in this area may
shed light on th pathophysiol gy of CLS associated with BMT and trigger he develop ent of novel
therapeutic approaches.
Besides IL-2 and BMT, we identified several potential causative drugs of CLS. The overall
estimation of CLS incidence by causative drugs varied from 3.5% (gemcitabine, three studies) to
100% (IL-2 + bevacizumab, one study). Studies with IL-2 + b vacizumab (one study, 100%) and IL-2
+ IFN-alpha 2a (two studies, overall estimation 85.5%, meta-analysis 90.4%) showed relatively high
CLS incidence proportions, while studies with gemcitabine (three studies, overall estimation 3.5%,
meta-analysis 4.9%) and GM-CSF (three studies, overall estimation 9.0%, meta-analysis 10.1%) showed
low incidence. Likewise, anti-cancer agents, including IL-2 + imatinib mesylate (three studies) and
anti-CD22 mAb (four studie ) showed a dose-dependent incr as in he incidence of CLS. Considering
the small number of studies, it is difficult to state whether there are dose-related trends for these agents.
Further studies should be performed to clarify this relationship in order to establish comprehensive
therapeutic guidelines, taking CLS as an adverse effect into account.
Several limitations of this study should be considered. First, the studies that we included were
not placebo-controlled trials with a control arm that would allow defining how much of the CLS was
attributable to treatment rather than the type and severity of the treated condition. Since the included
individual studies just reported the number of CLS as an adverse event of anti-cancer drugs, the
prognosis and long-term outcome of CLS could not be addressed. Therefore, further clinical trials
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or observational studies should attempt to address the prospective associations between CLS and
anti-cancer treatment. Second, coexisting conditions were not considered in our study. For example,
we extracted the name of the causative drug and its dose, but other effects such as drug combination or
cumulative effects may have affected the outcomes. Also, there might be other causes for CLS besides
anti-cancer treatment, so potential confounders should be acknowledged.
5. Conclusions
Our study is the first systematic analysis of the incidence of CLS in cancer patients treated with
various anti-cancer agents and therapy. The incidence of CLS due to IL-2 (18 studies) was 34.7% by
overall estimation and 43.9% by meta-analysis, and the corresponding figures for BMT were 21.1%
and 21.7%, respectively CLS was also reported in cases receiving other agents. Our study results
highlight the need for inclusion of the risk of development of CLS in the choice of treatment and
preparation of the appropriate management for cancer patients in anticipation of this syndrome. Thus,
we recommend that physicians and oncologists should be aware of secondary CLS in cancer patients
during anti-cancer treatment, and encourage careful observation to prevent CLS or enable timely
management when CLS develops.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/2/143/s1,
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